Switching from EFV/TDF/3TC to B/F/TAF or DTG/3TC in virologically suppressed PLWH shows no significant between-group metabolic differences over 24 months.
Switching HIV drugs showed similar metabolic changes over two years in this real-world study.
This retrospective real-world study evaluated 326 virologically suppressed persons with HIV (PLWH) switching from efavirenz/tenofovir disopr…
Switching HIV drugs caused similar weight gain and metabolic shifts over two years, meaning lifestyle factors matter more than the specific …
Phase 3 trial compares switch to doravirine/islatravir versus continuing bictegravir/FTC/TAF in HIV-1
Phase 3 trial compares two HIV drug regimens for people already virologically suppressed.
A phase 3 randomized controlled trial enrolled 643 virologically suppressed adults with HIV-1 to compare switching to doravirine/islatravir …
People with HIV already on effective treatment can safely switch to a new two-drug pill without losing virus control, according to a complet…
Bictegravir-lenacapavir single-tablet regimen non-inferior to complex regimens for HIV-1 suppression at 48 weeks
Can a single daily pill control HIV as well as complex multi-pill regimens?
In this phase 3 randomized trial of 557 virologically suppressed adults with HIV-1 on complex regimens, switching to once-daily oral bictegr…
A new single daily pill kept HIV suppressed just as well as complex multi-pill regimens in a trial of 557 adults who had been on treatment f…